An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression

Abstract excerpt

Diffuse large B cell lymphoma (DLBCL) is a complex disease comprising diverse subtypes and genetic profiles. Possibly because of the prevalence of genetic alterations activating canonical NF-κB activity, a role for oncogenic lesions that activate the alternative NF-κB pathway in DLBCL has remained elusive. Here, we show that deletion/mutation of TRAF3, a negative regulator of the alternative NF-κB pathway, occurs...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lymphoma Diagnosis and Treatment
• Share to NF-κB Signaling Pathways
• Share to T-cell and Retrovirus Studies